Recent News

• 06.11.2025 - Artelo Biosciences Announces Reverse Stock Split
• 06.05.2025 - Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
• 06.02.2025 - New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
• 05.13.2025 - Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
• 04.28.2025 - Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
• 03.31.2025 - Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
• 03.03.2025 - Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
• 02.14.2025 - Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
• 02.11.2025 - Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland
• 01.13.2025 - Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Recent Filings

• 05.23.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.01.2025 - 8-K Current report
• 04.29.2025 - 8-K Current report
• 03.20.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 12.23.2024 - 4 Statement of changes in beneficial ownership of securities